David Mazzo

Dr. David J.
Mazzo is a Chairman at Feldan Bio, Inc., a Chief Executive Officer & Director at Lisata Therapeutics, Inc., a Member at American Association of Pharmaceutical Scientists and a Member at AOAC International.
He is on the Board of Directors at Lisata Therapeutics, Inc. and Bonnie Brae, Inc. Dr. Mazzo was previously employed as a Chairman by Visioneering Technologies, Inc., an Independent Director by Seneca Biopharma, Inc., a President, Chief Executive Officer & Director by Caladrius Biosciences, Inc., a Chief Executive Officer & Executive Director by Regado Biosciences, Inc., a President, CEO & Executive Director by Æterna Zentaris, Inc., an Independent Director by Avanir Pharmaceuticals, Inc., an Independent Non-Executive Director by EyePoint Pharmaceuticals, Inc., a President, CEO & Executive Director by Chugai Pharma USA LLC, a Senior Vice President-Development Operations by Schering-Plough Research Institute, a Senior Director by Rhone-Poulenc Rorer, Inc., a Chief Executive Officer & Director by Essex Chimie AG, a SVP-Global Head Pharmaceutical Development by Hoechst Marion Roussel Ltd. (United Kingdom), and a Member by Roche Group.
He also served on the board at Essex SAS, Hoechst Marion Roussel, Inc. and Schering-Plough Corp.
USA. He received his undergraduate degree from Villanova University, a graduate degree from the University of Massachusetts and a doctorate degree from the University of Massachusetts.